| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Gene Therapies | Hematologic System | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Gene Therapies | Hematologic System | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Gene Therapies | Hematologic System |
Recent Updates
Recently added Catalysts
Geron Corporation$1.5
-0.06 (-3.85%)
C 42Pipeline Score Overvalued Biotech · Clinical
Market Cap
821.15 M
EPS
-0.10
P/E Ratio
-
Value Trade
11.69 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
51.84 M
R&D Expenses
14.96 M
Operating CF
-62.91 M
Total Assets
534.12 M
Total Liabilities
305.01 M
Equity
229.11 M
D/E Ratio
12,345
-8.57 %
Week
-16.34 %
1 Month
-32.63 %
3 Month
18.52 %
6 Month
-11.72 %
5 Year
-83.07 %
All Time
Cash Data
Cash Position
339.09 M
Monthly Burn
20.97 M
Runway
14.3 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
10.35 M
52 Week Range
1.04 - 2.01
% held by Insiders
2.19 %
% held by Institutions
75.9 %
Enterprise Value
758.70 M
Total Shares
641.19 M
Short %
11.93 %
Float Shares
625.80 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Geron Corporation
601Total events
5Upcoming
110Tier-1 (high impact)
2009 – 2028Coverage
Upcoming catalysts 5
Jul 30, 2026
T2Debt Royalty Financing
Amendment to extend Tranche B and Tranche C loan request deadline to July 30, 2026
Event history 596
Q3 2026
◆Interim AnalysisImetelstatApprovedTrial
IMpactMF interim analysis in relapsed/refractory myelofibrosis expected in second half of 2026
relapsed/refractory myelofibrosissource ↗
Q3 2026
◆Additional DataRYTELOApprovedClinical Data
First data from real-world experience trials in LR-MDS expected in second half of 2026
lower-risk MDSsource ↗
Jun 8, 2026
◆Oral PresentationPresentation
Geron management to participate in fireside chat at Goldman Sachs 47th Annual Global Healthcare Conference
May 20, 2026
May 12, 2026
◆Oral PresentationPresentation
Bank of America Securities 2026 Healthcare Conference presentation
May 6, 2026
▲Quarterly UpdateCorporate
Existing cash plus anticipated RYTELO revenues expected to fund operations for foreseeable future
May 6, 2026
▲PublicationImetelstatApprovedPresentation
Publication in Blood Cancer Journal on treatment-emergent cytopenias and clinical responses
lower-risk myelodysplastic syndromes (LR-MDS)source ↗
May 6, 2026
▲Manufacturing MilestoneRYTELOApprovedCMC / Inspection
Validation of a second supplier for RYTELO supply chain
May 6, 2026
●Management ChangeCorporate
Appointment of Timothy Williams as EVP, Chief Legal Officer and Corporate Secretary
Apr 13, 2026
●Management ChangeCorporate
Appointment of Timothy Williams as EVP, Chief Legal Officer and Corporate Secretary
Apr 13, 2026
◆Oral PresentationPresentation
Fireside chat at 25th Annual Needham Virtual Healthcare Conference
Q2 2026
◆Interim AnalysisImetelstatApprovedTrial
Expected interim analysis for overall survival in IMpactMF
relapsed/refractory myelofibrosissource ↗
Drug Pipeline Intelligence
C42
Pipeline Score $214M
Pipeline ValueOvervalued
Valuation Signal2
Drugs Scored0.3x
rNPV / MCap Top 61%
Micro Cap (rank 356 of 911)
Percentile RankGeron Corporation carries a moderate pipeline score (42/100), with $687M risk-adjusted pipeline value, led by imetelstat in Non-small Cell Lung Cancer (Phase 2), across $145B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Imetelstat Small molecule | Myelofibrosis | Phase 3 | NCT04576156 | 50% | $557M | ACTIVE NOT_RECRUITING | 470 | AVERAGE | C (56) | Jun 30, 2028 | LOW_RISK | LOW Jul 8, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
RYTELO | lower-risk myelodysplastic syndromes | — | 2025-12-08 | increased hemoglobin levels; transfusion independence | Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO (Imetelstat) in Lower-Risk MDS Read More | |
RYTELO | lower-risk myelodysplastic syndromes | — | 2025-12-08 | increased hemoglobin levels; transfusion independence | Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO (Imetelstat) in Lower-Risk MDS Read More | |
RYTELO | lower-risk myelodysplastic syndromes | — | 2025-12-08 | increased hemoglobin levels; transfusion independence | Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO (Imetelstat) in Lower-Risk MDS Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GERN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
GERN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
GERNGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation has announced the granting of stock options to eight new employees as an inducement for accepting employment. The options cover 690,000 shares with a ten-year term and an exercise price equal to the closing stock price. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is part of Geron's 2018 Inducement Award Plan. The vesting schedule includes incremental releases based on continued employment, indicating a long-term investment in new hires.
Read more →GERNGeron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Geron Corporation will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. The management team will engage in a fireside chat at 8:40 a.m. ET in Miami, FL. Geron is known for its first-in-class telomerase inhibitor, RYTELO® (imetelstat), which is approved for treating specific blood cancer patients.
Read more →GERNGeron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights
Geron Corporation reported a strong financial performance for Q1 2026, with RYTELO net product revenue reaching $51.8 million, an 8% increase from the previous quarter. The company also announced a strengthened leadership team and maintained a solid cash position of $341 million. Despite a net loss of $3.6 million, Geron remains optimistic about future growth and plans for RYTELO in the U.S. and Europe.
Read more →GERN▲ +5.1%on this newsshared move
Geron Plans to Present at Upcoming Investor Conferences
Geron Corporation has announced upcoming presentations at major investor conferences, including the Bank of America Securities 2026 Healthcare Conference and the 2026 Stifel Virtual Targeted Oncology Forum. These presentations are scheduled for May 12 and May 20, 2026, respectively. Geron aims to showcase its initiatives in changing the course of blood cancer, positioning itself for potential investor interest.
Read more →GERNGeron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026
Geron Corporation plans to release its first quarter 2026 financial results on May 6, 2026. The announcement will be made before the market opens, followed by a conference call at 8:00 a.m. ET. Geron is focused on blood cancer treatments, particularly with its telomerase inhibitor RYTELO® and ongoing clinical trials.
Read more →GERNGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 20, 2026
Geron Corporation announced the grant of stock options to nine new employees as an inducement for their acceptance of employment. The options, totaling 855,000 shares, have an exercise price of $1.68 per share and will vest over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to bolster the company's workforce as it continues its focus on blood cancer therapies.
Read more →GERNGeron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 14, 2026
Geron Corporation announced the granting of a stock option to Timothy Williams, its new Executive Vice President, as part of his employment agreement. The option allows him to purchase 2,500,000 shares at an exercise price of $1.73, vesting over four years. This grant was approved by the Compensation Committee under Nasdaq rules.
Read more →GERNGeron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation has granted a stock option to Timothy Williams, its new Executive Vice President, as part of his employment agreement. The option allows him to purchase 2.5 million shares at an exercise price of $1.73, vesting over four years. This grant complies with Nasdaq regulations and reflects Geron's commitment to attracting top talent.
Read more →GERNGeron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary
Geron Corporation has appointed Timothy Williams as Executive Vice President, Chief Legal Officer, and Corporate Secretary. Williams, who has a strong background in the biopharmaceutical industry, is expected to provide strategic counsel as Geron advances its mission in hematology. His previous experience includes roles at Vanda Pharmaceuticals and AgNovos Bioscience.
Read more →GERN▲ +5.4%on this news
Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference
Geron Corporation will participate in the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026. The management team will engage in a fireside chat, which will be available via live and archived audio webcast. Geron focuses on developing treatments for blood cancer, including its approved telomerase inhibitor, RYTEL®.
Read more →GERNGeron Announces Appointment of New Members to its Board of Directors
Geron Corporation has appointed Patricia S. Andrews and Constantine Chinoporos to its Board of Directors. Both bring extensive experience in the biopharmaceutical industry, which is expected to support Geron's strategic priorities and commercial growth for its treatment, RYTELO. The new board members expressed optimism about the company's future and its potential impact on patients with lower-risk myelodysplastic syndromes.
Read more →GERN▼ -11.8%on this news
Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Geron Corporation reported its financial results for Q4 and the full year 2025, highlighting $48 million in net product revenue for Q4 and $184 million for the year from RYTELO. The company aims to drive demand growth while managing operating expenses, which totaled $255 million for 2025. Geron ended the year with approximately $401 million in cash and equivalents, positioning itself for future growth in the hematology market.
Read more →GERNGeron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
Geron Corporation announced that it will release its fourth quarter and full year 2025 financial results on February 25, 2026. The results will be shared via press release before the market opens, followed by a conference call and webcast. Geron continues to focus on advancing its blood cancer treatments, including its approved drug RYTELOR and ongoing clinical trials.
Read more →GERN▲ +6.7%on this news
Geron Corporation Provides 2026 Financial Guidance
Geron Corporation has published its financial guidance for 2026, expecting RYTELO (imetelstat) net product revenue to range between $220 million and $240 million. The company anticipates total operating expenses within a similar range, reflecting a strategic restructuring to streamline operations. CEO Harout Semerjian emphasized their commitment to advancing RYTELO's commercial growth and clinical trials, while CFO Michelle Robertson noted that the guidance indicates an expected year-over-year reduction in operating expenses. The announcement also highlighted new scientific evidence supporting RYTELO's efficacy presented at the 2025 ASH Annual Meeting.
Read more →GERN▲ +8.6%on this news
Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation
Geron Corporation has announced a strategic restructuring plan aimed at enhancing long-term value for patients and shareholders. The plan includes a significant workforce reduction and is expected to lower operating expenses for 2026. The company remains committed to advancing the commercial growth of RYTELO and continuing its Phase 3 clinical trials.
Read more →GERNGeron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO (Imetelstat) in Lower-Risk MDS
Geron Corporation presented new data at the ASH 2025 Annual Meeting, emphasizing the relationship between treatment-emergent cytopenias and clinical benefits associated with RYTELO (imetelstat) in lower-risk myelodysplastic syndromes (LR-MDS). The oral presentation highlighted that early cytopenias may predict meaningful outcomes such as increased hemoglobin levels and transfusion independence. Long-term analyses from the IMerge trial showcased improved survival trends among imetelstat-treated patients compared to placebo. These findings support the potential of imetelstat as a disease-modifying treatment for patients with LR-MDS.
Read more →GERN▼ -5.2%on this news
Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights Achieved $47.2 million in RYTELO net product revenue in Q3 2025 Completed enrollment in Phase 3 IMpactMF clinical trial evalua
Geron Corporation reported a strong third quarter for 2025, achieving $47.2 million in net product revenue from RYTELO while completing enrollment in the Phase 3 IMpactMF clinical trial. The company has made significant strides in strengthening its leadership team and has announced several upcoming presentations at major hematology conferences. However, there was a 3% decrease in demand quarter-over-quarter, and total operating expenses rose compared to the previous year. Geron is focused on maximizing the potential of RYTELO and enhancing patient awareness for ongoing and future clinical endeavors.
Read more →GERNGERON (GERN) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is conducting an investigation into Geron Corporation on behalf of long-term stockholders due to a class action complaint. The complaint alleges that the company's board may have breached its fiduciary duties concerning the expectations for the launch and sales potential of its drug, Rytelo. Concerns are raised regarding the accuracy of information provided to investors, particularly the risks associated with the drug's commercialization and competition in the market.
Read more →GERNGeron Corporation Announces Executive Leadership Transitions and Appointments
Geron Corporation has announced significant executive leadership changes, including the departure of COO Andrew Grethlein and CCO Jim Ziegler. Ahmed ElNawawi has been appointed as the new CCO to drive the company's strategic priorities, particularly focusing on RYTELO. The company aims to enhance its leadership team to better position itself in the blood cancer treatment market.
Read more →GERNGeron Corporation Investors: Company Investigated by the Portnoy Law Firm
Geron Corporation is under investigation by the Portnoy Law Firm for potential securities fraud, with a class action possibly on the horizon for affected investors. The investigation highlights concerns regarding statements made about the drug Rytelo (imetelstat) and its market potential, where risks related to monitoring requirements and competition were allegedly minimized. Investors are being encouraged to seek legal advice and explore their options for recovering losses.
Read more →GERN▲ +5.9%on this newsshared move
GERON (GERN) ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Geron Corporation on behalf of long-term stockholders due to a class action complaint filed on March 14, 2025. The investigation focuses on allegations of breaches of fiduciary duties by Geron's board of directors. The complaint claims that Geron misled investors about the commercial potential of its drug Rytelo (imetelstat) while downplaying significant risks. Stakeholders with information or questions are encouraged to contact the law firm for further guidance.
Read more →GERN▲ +15.8%on this news
Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights Seasoned Commercial Hematology and Oncology Leader Harout Semerjian Appointed as President and CEO Achieved $49.0 million in
Geron Corporation reported its second-quarter 2025 financial results, highlighting significant commercial achievements with RYTELO, which generated $49 million in net product revenue. The company announced the appointment of Harout Semerjian as President and CEO, aiming to strengthen its leadership in hematology and oncology. Enrollment for the Phase 3 IMpactMF clinical trial is over 95% complete, with expectations to finalize by year-end. However, the company reported a net loss and a decrease in cash reserves, indicating ongoing financial pressures despite revenue growth.
Read more →GERNGERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Geron Corporation on behalf of long-term stockholders after a class action complaint was filed. The lawsuit claims that Geron misled investors about the commercial prospects for its drug, Rytelo, during a specified class period. Allegations suggest the company's board may not have adequately disclosed risks related to the drug's monitoring requirements and competitive pressures. The law firm is actively seeking long-term stockholder input regarding these issues.
Read more →GERN▲ +8.5%on this news
Geron Corporation Investors: Please contact the Portnoy Law Firm to recover your losses. May 12 2025 Deadline to file Lead Plaintiff Motion.
Geron Corporation is currently involved in a class action lawsuit following allegations of misleading statements about its revenue prospects and the launch of its drug Rytelo. The lawsuit claims that the company downplayed various risks affecting sales, including seasonality and competition. Following a recent announcement that revealed stagnation in Rytelo's growth, Geron's stock experienced a significant decline of more than 32%. Investors who purchased shares during the specified class period are encouraged to contact the Portnoy Law Firm for potential recovery options.
Read more →GERNGeron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights Reported $39.4 million in RYTELO (imetelstat) net product revenue in Q1 2025 revenue impacted by inventory dynamics, with Q1 d
Geron Corporation announced its first quarter 2025 financial results, reporting $39.4 million in net product revenue from RYTELO. The company's revenue was affected by inventory dynamics, and demand remained flat. Geron received marketing authorization for RYTELO from the European Commission and is planning to launch it in select EU countries by 2026. The company also reported reaching 85% enrollment in the Phase 3 IMpactMF clinical trial, with an interim analysis expected in the second half of 2026.
Read more →GERNGeron Corporation Investors: Please contact the Portnoy Law Firm to recover your losses. May 12 2025 Deadline to file Lead Plaintiff Motion
Geron Corporation is facing a class action lawsuit from investors who purchased securities between February 28, 2024, and February 25, 2025. The lawsuit claims the company misrepresented its financial outlook and the market potential of its drug, Rytelo, leading to a significant decline in its stock price. After reporting stagnant growth attributed to seasonality and competition, Geron's stock fell by over 32% following the fourth quarter report for fiscal 2024. Investors are encouraged to contact the Portnoy Law Firm for legal support.
Read more →GERNGeron Corporation Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 12, 2025 to Discuss Your Rights – GERN
Geron Corporation is facing a class action lawsuit by Levi & Korsinsky for alleged securities fraud affecting investors between February 28, 2024, and February 25, 2025. The lawsuit highlights misleading information regarding the launch and growth potential of Rytelo, significantly impacting its market performance. Following the announcement of dwindling growth for Rytelo, Geron's stock plummeted by over 32%. Investors wishing to join the class action have until May 12, 2025, to take action.
Read more →GERNGERON ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Geron Corporation and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has announced the filing of a class action lawsuit against Geron Corporation, targeting investors who purchased securities between February 28, 2024, and February 25, 2025. The complaint accuses the company of providing misleading information about the expected growth and market potential of Rytelo while downplaying associated risks. Investors are encouraged to contact the law firm for participation in the case. The deadline for applying as a lead plaintiff in the lawsuit is May 12, 2025.
Read more →GERN▲ +6.1%on this newsshared move
Geron Corporation Shareholder Notice: Robbins LLP Reminds Investors of the Pending GERN Class Action Lawsuit
Robbins LLP has filed a class action lawsuit on behalf of investors who bought Geron Corporation securities between June 7, 2024, and February 25, 2025. The lawsuit alleges that Geron misled investors about the launch success and growth potential of its blood cancer product, Rytelo. Following the announcement of flat growth due to several operational issues, Geron's stock experienced a significant decrease in value. Shareholders have until May 12, 2025, to participate as lead plaintiffs in the lawsuit.
Read more →GERN▲ +6.1%on this newsshared move
Geron Corporation Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before May 12, 2025 to Discuss Your Rights – GERN
Geron Corporation is facing a securities fraud class action lawsuit following a significant drop in its stock price. The firm, Gross Law, has alerted shareholders who purchased shares from June 7, 2024, to February 25, 2025, to register their information for the case. Allegations include misleading statements about Rytelo's market potential and the risks associated with its monitoring requirements. Following the release of fourth-quarter financial results that showed weakened growth for Rytelo, Geron's stock plummeted by over 32% in one day.
Read more →GERNGERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Geron Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Geron Corporation on behalf of its stockholders concerning potential violations of federal securities laws. This follows Geron's announcement of flat revenue trends for its blood-disorder drug, Rytelo, which contributed to a significant decline in the company's stock price on February 26, 2025. Investors who have suffered losses or have information regarding these matters are encouraged to contact the law firm. The investigation may indicate broader issues with the company's business practices.
Read more →GERN▼ -32.1%on this news
Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights Achieved $47.5 million in RYTELO (imetelstat) net product revenue in Q4 2024 and $76.5 million since commercial
Geron Corporation reported strong financial results for the fourth quarter and full year of 2024, with RYTELO (imetelstat) generating $47.5 million in net product revenue in Q4 alone. The company expects to achieve profitability without the need for additional financing, contingent on current sales and operational performance. Additionally, Geron received a favorable opinion from the European Medicines Agency for RYTELO's approval in Europe and continues to advance its Phase 3 trial in myelofibrosis. However, they also reported a net loss of $25.4 million in Q4 2024.
Read more →GERNCorporate Presentation Our mission is to change lives by changing the course of blood cancer January 2025 Our mission is to change lives by changing the course of blood cancer Forward-Looking Statements Except for the hi
Geron's recent corporate presentation emphasizes their mission to transform the treatment landscape for blood cancer, particularly through their therapy RYTELO (imetelstat). The company believes RYTELO holds blockbuster potential, specifically for lower-risk myelodysplastic syndromes (LR-MDS) patients, and projects significant revenue growth. However, the path to market is fraught with uncertainties, including the need for regulatory approvals and the potential for adverse events that may hinder commercialization. Geron also emphasizes their commitment to navigating the complexities of clinical trials and market strategies to ensure successful product launch and profitability.
Read more →GERNGeron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights Achieved $28.2 million in RYTELO (imetelstat) net product revenue in first full quarter of sales Received $250 million in gros
Geron Corporation reported strong financial results for Q3 2024, with $28.2 million in revenue from RYTELO during its first full quarter of sales. The company secured $250 million in financing through synthetic royalty and debt transactions, enhancing its cash position for future investments. Despite a net loss of $26.4 million and rising operating expenses, the positive sales performance indicates strong market demand for RYTELO in treating lower-risk MDS. The company also prepares for regulatory reviews and potential launch in the EU by 2026.
Read more →GERNGeron Corporation Reports Second Quarter 2024 Financial Results and Business Highlights U.S. commercial launch of RYTELO (imetelstat) began in June 2024 for patients with lower-risk myelodysplastic syndromes (LR-MDS) wit
Geron Corporation has launched RYTELO (imetelstat), its first commercial product, for patients with lower-risk myelodysplastic syndromes. The launch in June 2024 has been met with positive reception from healthcare professionals, with approximately 160 patients treated within the first six weeks. The National Comprehensive Cancer Network updated its guidelines to include RYTELO, supporting its adoption in clinical practice. Despite the promising start, Geron reported a significant net loss and rising operational expenses in its financial results for the second quarter of 2024.
Read more →GERN▲ +18%on this news· ran to +31% by day 3
Geron Announces FDA Approval of RYTELO (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia • Approval across ESA ineligibl
Geron Corporation announced the FDA's approval of RYTELO (imetelstat), the first telomerase inhibitor for treating adult patients with lower-risk myelodysplastic syndromes (LR-MDS) and transfusion-dependent anemia. The approval is based on the results of the IMerge Phase 3 clinical trial, which showed significant rates of red blood cell transfusion independence. The approval addresses a high unmet need in this patient population, providing a potential for improved clinical outcomes. RYTELO's application aligns with the necessary monitoring protocols due to associated cytopenias.
Read more →GERNGeron Corporation Reports First Quarter 2024 Financial Results and Business Highlights
Geron Corporation has reported its financial results for the first quarter of 2024, with a substantial net loss of $55.4 million. The company is gearing up for the potential commercial launch of its drug imetelstat, with a crucial PDUFA date set for June 16, 2024. Additionally, the Phase 3 IMpactMF clinical trial is progressing, although timelines for interim analysis have been extended. Geron has also strengthened its commercial team in anticipation of the drug's approval and market entry.
Read more →GERNRisk Factor Summary Below is a summary of material factors that make an investment in our common stock speculative or risky. Importantly, this summary does not address all of the risks and uncertainties that we face. You
The article outlines various speculative and risky elements associated with investing in GERN's common stock, emphasizing that imetelstat is the sole product candidate. It highlights the dependence on successful development and regulatory approval of imetelstat, which faces multiple uncertainties, including potential adverse effects and reliance on third-party trials. Additional financial challenges include the need for capital and high indebtedness, contributing to the overall risk profile of GERN. The company's success is intertwined with the commercial viability of imetelstat, facing fierce competition and compliance challenges.
Read more →GERN▲ +92%on this newsshared move
Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS • FDA Onco
Geron Corporation announced that the FDA Oncologic Drugs Advisory Committee voted 12 to 2 in favor of the clinical benefit/risk profile of imetelstat for treating transfusion-dependent anemia in adult patients with lower-risk myelodysplastic syndromes (LR-MDS). The vote was based on promising results from the IMerge Phase 3 clinical trial, which demonstrated high rates of red blood cell transfusion independence. Geron anticipates the FDA will issue a decision by the PDUFA target action date of June 16, 2024, as the company prepares for a potential commercial launch of imetelstat.
Read more →GERN▼ -5.6%on this news
Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Geron Corporation has reported its fourth quarter and full year 2023 financial results, detailing a strong outlook as it prepares for the potential U.S. commercial launch of imetelstat on June 16, 2024. The company achieved positive results from pivotal clinical trials and made progress on regulatory submissions. However, Geron also faced high operating expenses and low revenue, despite having sufficient financial resources to support operations into 2025. The appointment of experienced executives further strengthens its leadership as it transitions to a commercial-stage company.
Read more →GERNCompany Logo Enhancing the Lives of Patients with Hematologic Malignancies Corporate Presentation January 2024 Forward-Looking Statements and Safe Harbor Except for the historical information contained herein, this prese
Geron Corporation is positioned for a lucrative transition to a commercial entity in 2024, focusing on the approval and launch of imetelstat for the treatment of transfusion-dependent low- to intermediate-1 risk myelodysplastic syndromes. The company anticipates a PDUFA date of June 16, 2024, for U.S. approval and potential EU launch by 2025. Imetelstat is expected to address significant unmet needs in these conditions, with estimated total addressable markets exceeding $3.5 billion in both the U.S. and EU. However, the company faces regulatory and clinical development risks that could impact these timelines.
Read more →GERN▼ -7.8%on this news
Geron Corporation Reports Business Highlights and Third Quarter 2023 Financial Results Imetelstat is currently under regulatory review by the FDA and EMA for the treatment of transfusion-dependent anemia in adult patient
Geron Corporation announced its third quarter 2023 financial results, highlighting progress in the regulatory review of imetelstat for the treatment of transfusion-dependent anemia in lower risk MDS by the FDA and EMA. The company plans for a potential commercial launch of imetelstat in mid-2024, supported by a robust financial position with $382 million available. While operating expenses have risen significantly, Geron's leadership feels confident about the product's market potential and execution capabilities moving forward.
Read more →GERNGeron Corporation Reports Business Highlights and Second Quarter 2023 Financial Results Submitted U.S. New Drug Application in lower risk MDS in June 2023 Additional data and analyses from IMerge Phase 3 presented at med
Geron Corporation reported significant advancements in its business for Q2 2023, including the submission of a New Drug Application for imetelstat aimed at treating lower-risk myelodysplastic syndromes (MDS). The company has highlighted promising results from its IMerge Phase 3 trial, showcasing the drug's benefits, including durable transfusion independence and improved patient outcomes. With a robust financial position of approximately $400 million in resources, Geron is well-prepared for a potential U.S. commercial launch in the first half of 2024.
Read more →GERNGeron Corporation Reports First Quarter 2023 Financial Results and Business Highlights Planned submission of U.S. New Drug Application on track for June 2023 Additional data and analyses from IMerge Phase 3 expected to b
Geron Corporation reported its financial results for the first quarter of 2023, highlighting key business developments and upcoming regulatory submissions. The company is preparing to submit a New Drug Application for imetelstat in June 2023 and anticipates a U.S. commercial launch in the first half of 2024. Geron has over $400 million on its balance sheet, providing financial cushioning through 2025. Although there was a net loss for the quarter, the company remains optimistic about imetelstat's potential in treating lower risk myelodysplastic syndromes (MDS).
Read more →GERNGERON CORPORATION (NASDAQ: GERN) INVESTOR UPDATE: NOTICE OF NEW DEADLINE TO FILE CLAIM OR REQUEST TO BE EXCLUDED FROM THE CLASS; Important Claims Filing Deadline in Proposed Settlement in the Geron Securities Litigation Has Been Extended to July 14, 2023
Geron Corporation has announced a new deadline for Class members involved in its securities litigation, allowing claims or exclusion requests to be submitted by July 14, 2023. This update is part of a proposed settlement process, which aims to resolve claims stemming from stock purchases made between March 19, 2018, and September 26, 2018. A Settlement Fairness Hearing is set for August 24, 2023, to evaluate the settlement's fairness and reasonableness. Class members are advised to carefully follow submission guidelines to ensure their eligibility.
Read more →GERNnd Annual Needham Virtual Healthcare Conference Slides
nd Annual Needham Virtual Healthcare Conference Slides
Read more →GERNIN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE GERON CORPORATION STOCKHOLDER DERIVATIVE LITIGATION ) ) Consolidated C.A. No. 2020-0684-SG NOTICE OF PENDENCY OF SETTLEMENT OF DERIVATIVE LITIGATION TO: ALL CURRENT
The notice outlines the proposed settlement of derivative litigation against Geron Corporation concerning alleged breaches of fiduciary duty by its officers and directors. Plaintiffs have filed several complaints against the company's leadership regarding misleading statements about clinical trial results. Current stockholders are informed about their rights to object to the settlement and to participate in a telephonic hearing scheduled for May 17, 2023. Approval of the settlement could result in the court issuing a final judgment that would conclude the derivative litigation.
Read more →GERNGeron Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Milestones Positive Phase 3 Top-Line Results in Lower Risk MDS Reported in January 2023 Planned 2023 Regulatory Submissions in th
Geron Corporation announced positive Phase 3 results for its drug imetelstat aimed at treating lower risk myelodysplastic syndromes (MDS). The company plans to submit regulatory applications in both the U.S. and EU throughout 2023, anticipating a potential commercial launch in 2024. Despite losses recorded in 2022 and a decline in revenue, Geron has raised substantial funds to support these efforts. The trial for relapsed/refractory myelofibrosis (MF) is also ongoing, with an interim analysis expected in 2024.
Read more →GERN▲ +32.9%on this news
by these cautionary statements. ********* Company Overview Summary We are a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic ma
Geron Corporation, a late-stage biopharmaceutical company, is advancing its investigational telomerase inhibitor, imetelstat, targeting hematologic malignancies. Recent results from the IMerge Phase 3 trial demonstrated significant efficacy, leading to plans for a New Drug Application in the U.S. and a marketing authorization application in Europe for lower risk myelodysplastic syndromes (MDS). The anticipated commercial launch could occur as early as the first half of 2024 in the U.S. if the NDA is approved. Geron is also exploring additional treatments for related hematologic conditions, bolstered by promising trial data.
Read more →GERNIN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE GERON CORPORATION STOCKHOLDER DERIVATIVE LITIGATION ) ) Consolidated C.A. No. 2020-0684-SG STIPULATION OF SETTLEMENT This Stipulation of Settlement (“Stipula
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE STIPULATION OF SETTLEMENT This Stipulation of Settlement ( Stipulation ) is made and entered into as of December 21, 2022, between and among, (a)(i) plaintiffs in the above-captioned consolidated derivative action (the Action ),
Read more →GERN▼ -5.6%on this news
Geron Corporation Reports Third Quarter 2022 Financial Results and Upcoming Expected Milestones Top-Line Results from IMerge Phase 3 Trial in Lower Risk MDS Continue to be Expected in Early January 2023 Current and Proje
Geron Corporation Reports Third Quarter 2022 Financial Results and Upcoming Expected Milestones Top-Line Results from IMerge Phase 3 Trial in Lower Risk MDS Continue to be Expected in Early January 2023 Current and Projected Financial Resources Expected to Support Planned Miles
Read more →GERNStipulation and Agreement of Settlement, dated
EXHIBIT 99.1 Stipulation and Agreement of Settlement, dated September 2, 2022 KAPLAN FOX & KILSHEIMER LLP Laurence D. King (SBN 206423) Kathleen A. Herkenhoff (SBN 168562) Blair E. Reed (SBN 316791) 1999 Harrison Street, Suite 1560 Oakland, CA 94612 Telephone: (415) 772-4700 Facs
Read more →GERN▼ -5.5%on this news
Press Release Dated
Press Release Dated, August 11, 2022 Geron Corporation Reports Second Quarter 2022 Financial Results Top-Line Results from IMerge Phase 3 Trial in Lower Risk MDS Continue to be Expected in Early January 2023 Current and Projected Financial Resources Expected to Support Planned
Read more →GERNJANUARY 2022
JANUARY 2022 CORPORATE PRESENTATION SLIDES
Read more →GERNGERON CORPORATION INVESTOR ALERT: Geron Investors Who Have Held Their Stock Continuously Since At Least March 2018 Encouraged To Contact Kehoe Law Firm, P.C.
PHILADELPHIA, April 20, 2021 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. is investigating whether certain officers and/or directors of Geron Corporation (“Geron”) (NASDAQ: GERN) breached their fiduciary duties to Geron and the Company’s shareholders. The investigation concerns whet
Read more →GERNJANUARY 2021
JANUARY 2021 CORPORATE PRESENTATION HANDOUT
Read more →GERNGeron Corporation Reports Third Quarter 2020 Financial Results and Current Events
FOSTER CITY, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2020. The Company will host a conference call today at 4:30 p.m. ET
Read more →GERNGeron Receives Positive Opinion from the EMA Committee for Orphan Medicinal Products for Orphan Drug Designation in the European Union for Imetelstat to Treat Myelodysplastic Syndromes
Designation would provide 10-year period of marketing exclusivity in the European Union after product approval Patients are currently enrolling in a Geron-sponsored Phase 3 clinical trial in lower risk myelodysplastic syndromes MENLO PARK, Calif., July 01, 2020 (GLOBE NEWSWIRE)
Read more →GERNGeron Reports Four Imetelstat Data Presentations at Virtual Edition of the European Hematology Association (EHA) Annual Congress
For the IMerge Phase 2 clinical trial, meaningful and durable transfusion independence reported with a new 1-year TI rate, indicating potential disease-modifying activity of imetelstat treatment For the IMbark Phase 2 clinical trial, the analyses correlate the potential improvem
Read more →GERNGeron Corporation Reports First Quarter 2020 Financial Results
MENLO PARK, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the first quarter ended March 31, 2020. The Company will host a conference call today at 4:30 p.m. ET to discuss the recently announced planned Phase 3 clini
Read more →GERNGeron Corporation Announces the Closing of its Public Offering of Common Stock and Warrants
MENLO PARK, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 107,049,375 shares of its common stock and pre-funded wa
Read more →GERNGeron Corporation Announces the Pricing of its Public Offering of Common Stock and Warrants
MENLO PARK, Calif., May 22, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 107,049,375 shares of its common stock and pre-funded wa
Read more →GERNGeron Corporation Announces Proposed Public Offering of Common Stock and Warrants
MENLO PARK, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock in
Read more →GERNGeron Announces Plans for Imetelstat Phase 3 Clinical Trial in Myelofibrosis and Other Updates
Geron plans to move forward with a Phase 3 clinical trial in refractory myelofibrosis (MF) with overall survival (OS) as a primary endpoint, which is expected to open for screening and enrollment in first quarter 2021 Completion of patient enrollment for the ongoing IMerge Phase
Read more →GERNGeron to Present at Needham Virtual Healthcare Conference
MENLO PARK, Calif., April 08, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to present a company overview at the 19th Annual Needham Virtual Healthcare Conference at 10:00
Read more →GERNGeron Provides COVID-19 Related Business Update
MENLO PARK, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical development biopharmaceutical company, today announced an update to information from its March 12 year-end conference call related to the impact of the COVID-19 pandemic
Read more →GERNDATED MARCH 12, 2020 Geron Corporation Reports Fourth Quarter and Full Year 2019 Financial Results and 2020 Milestones Conference Call Scheduled for 4:30 p.m. ET today
Geron Corporation Reports Fourth Quarter and Full Year 2019 Financial Results and 2020 Milestones Conference Call Scheduled for 4:30 p.m. ET today MENLO PARK, Calif., March 12, 2020 -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing
Read more →GERNGeron Corporation Reports Fourth Quarter and Full Year 2019 Financial Results and 2020 Milestones
MENLO PARK, Calif., March 12, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies, today reported financial results for t
Read more →GERNGERON DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Geron Corporation To Contact The Firm
NEW YORK, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Geron Corporation (“Geron” or the “Company”) (NASDAQ:GERN) of the March 23, 2020 deadline to seek the role of lead plaintiff in a federal securities clas
Read more →GERNGERON CORPORATION INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action has been filed in the United States District Court for the Northern District of California on behalf of investors in Geron Corporation
NEW YORK, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors that purchased Geron Corporation (“Geron”
Read more →GERNJANUARY 2020
JANUARY 2020 CORPORATE PRESENTATION HANDOUT
Read more →GERN, Dated
Press Release, Dated December 18, 2019 Geron Conducts End of Phase 2 Meeting for Imetelstat in Relapsed/Refractory Myelofibrosis MENLO PARK, Calif., December 18, 2019 - Geron Corporation (Nasdaq: GERN) today announced that the Company has conducted an End of Phase 2 meeting wit
Read more →GERNGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 150,000 shares of Geron common stock as inducements to two newly-hired employees in connection with co
Read more →GERNGeron Corporation Reports Third Quarter 2019 Financial Results and Recent Events
MENLO PARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the third quarter and year-to-date as of September 30, 2019 as well as recent events. The Company ended the third quarter with $159.3 million in cash and ma
Read more →GERNGeron Announces Two Poster Presentations at Upcoming American Society of Hematology Annual Meeting
MENLO PARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that two abstracts related to imetelstat, the Company’s first-in-class telomerase inhibitor, have been accepted for presentation at the 61st American Society of Hematology (ASH)
Read more →GERNGeron to Announce Third Quarter Financial Results on November 6, 2019
MENLO PARK, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2019 financial results after the market closes on Wednesday, November 6, 2019 via press release, which will be available on the Company’s
Read more →GERNGeron Announces First Patient Dosed in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes
MENLO PARK, Calif., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the first patient has been dosed in the IMerge Phase 3 clinical trial to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes
Read more →GERNGeron Announces Fast Track Designation Granted to Imetelstat for Relapsed/Refractory Myelofibrosis
MENLO PARK, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to imetelstat for the treatment of adult patients with Intermediate-2 or High-risk
Read more →GERNGeron to Present at 2019 Cantor Global Healthcare Conference
MENLO PARK, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to present a company overview at the 2019 Cantor Global Healthcare Conference in New York at 9:3
Read more →GERNGeron Starts Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes
MENLO PARK, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the opening of patient screening and enrollment for the Phase 3 portion of IMerge to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic sy
Read more →GERNGeron Corporation Reports Second Quarter 2019 Financial Results and Recent Events
MENLO PARK, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the second quarter ended June 30, 2019, and recent events. The Company ended the second quarter with $162.3 million in cash and marketable securities. Duri
Read more →GERNGeron to Announce Second Quarter Financial Results on August 1, 2019
MENLO PARK, Calif., July 25, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will release its second quarter 2019 financial results after the market closes on Thursday, August 1, 2019 via press release, which will be available on the Company’s we
Read more →GERNGeron Enhances Oncology Expertise to Advance Corporate Objectives
MENLO PARK, Calif., July 18, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the appointments of Sharon McBain as Vice President, Global Regulatory Affairs and Lynn Bodarky as Vice President, Business Development. These appointments further enhance the C
Read more →GERNGeron Appoints Vice President, Human Resources
MENLO PARK, Calif., June 20, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the appointment of Shannon Odam as Vice President, Human Resources. Ms. Odam joins other recently recruited senior leadership to further strengthen the organization as it expand
Read more →GERNGeron Reports Two Imetelstat Data Presentations at European Hematology Association Annual Congress
Updated 8-week RBC-TI rate for the Phase 2 portion of IMerge increased to 42%, from 37% in December 2018 Updated 24-week RBC-TI rate for the Phase 2 portion of IMerge increased to 29%, from 26% in December 2018 Statistical analyses comparing IMbark clinical trial data to closel
Read more →GERNGeron to Webcast KOL Event on June 25, 2019
MENLO PARK, Calif., June 10, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the Company will webcast an event on June 25, 2019, featuring key opinion leaders (KOLs) who are authors of imetelstat data presentations being made at the 24th Annual Cong
Read more →GERNGeron Provides Imetelstat Program Update Conference Call Scheduled for 9:00 a.m. ET today
Geron Provides Imetelstat Program Update Conference Call Scheduled for 9:00 a.m. ET today MENLO PARK, Calif., May 16, 2019 -- Geron Corporation (Nasdaq: GERN) today provided an update to its 2019 corporate objectives for the imetelstat program. "2019 is off to a good start wit
Read more →GERNGeron Continues to Build Senior Leadership of Its Development Team
MENLO PARK, Calif., May 16, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it is continuing to build the senior leadership of its development team with the addition of a Vice President, Biometrics, and a Vice President, Manufacturing. Their oncolog
Read more →GERNGeron Provides Imetelstat Program Update
MENLO PARK, Calif., May 16, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today provided an update to its 2019 corporate objectives for the imetelstat program. “2019 is off to a good start with the imetelstat IND transfer now complete, enabling us to move forward wit
Read more →GERNGeron Announces Two Presentations on Imetelstat at Upcoming European Hematology Association Annual Congress
MENLO PARK, Calif., May 16, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that two abstracts containing clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, have been accepted for presentation at the 24th
Read more →GERNGeron Corporation Reports First Quarter 2019 Financial Results
MENLO PARK, Calif., May 02, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the first quarter ended March 31, 2019. As of the quarter-end, the Company had approximately $170 million in cash and marketable securities, which is suffici
Read more →GERNGeron Expands Senior Leadership of Its Development Team
MENLO PARK, Calif., April 18, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced an expansion of its development team’s senior leadership with the addition of three highly experienced professionals for key functional areas. Their oncology and drug developme
Read more →GERNGeron to Present at Needham Healthcare Conference
MENLO PARK, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to present a company overview at the 18th Annual Needham Healthcare Conference in New York at 3:
Read more →GERNGeron Appoints Two New Independent Board Members
MENLO PARK, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the appointments of Dawn C. Bir and Elizabeth G. O’Farrell as independent members of its Board of Directors. In addition, Ms. Bir will serve as a member of the Board’s Nominati
Read more →GERNGeron Corporation Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Events
MENLO PARK, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the fourth quarter and full year ended December 31, 2018 and recent events. As of year-end 2018, the Company had approximately $182 million in cash and mar
Read more →GERNDATED MARCH 7, 2019 Geron Corporation Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Events Conference Call Scheduled for 4:30 p.m. ET today
Geron Corporation Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Events Conference Call Scheduled for 4:30 p.m. ET today MENLO PARK, Calif., March 7, 2019 -- Geron Corporation (Nasdaq: GERN) today reported financial results for the fourth quarter and ful
Read more →GERNGeron to Announce Fourth Quarter and Full Year 2018 Financial Results on March 7, 2019
MENLO PARK, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2018 financial results after the market closes on Thursday, March 7, 2019 via press release, which will be available on the
Read more →GERNGeron Announces Expansion of Leadership Team with Appointment of Chief Medical Officer
Aleksandra Rizo, M.D., Ph.D., former clinical lead for the imetelstat program at Janssen, joins Geron as Chief Medical Officer Additional office to be opened in New Jersey to support expansion of clinical development team Preliminary operating expense guidance for 2019 provided
Read more →GERNGeron Appoints Vice President, Pharmacovigilance and Drug Safety
MENLO PARK, Calif., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the hiring of the first of several key leadership positions as it rebuilds the in-house development team to support its plans to initiate a Phase 3 clinical trial of imetelstat
Read more →GERNJANUARY 2019
JANUARY 2019 CORPORATE PRESENTATION HANDOUT
Read more →GERNGeron Announces New Board Leadership Structure
CEO John A. Scarlett Appointed Chairman Karin Eastham Appointed Lead Independent Director MENLO PARK, Calif., Dec. 31, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced changes to the leadership structure of the Company’s Board of Directors. For personal
Read more →GERNGeron Announces New Overall Survival Data from IMbark in Imetelstat-Treated Patients with Intermediate-2 or High-Risk Myelofibrosis and Relapsed/Refractory to Janus Kinase Inhibitor Therapy
Data Reporting Median Overall Survival of 29.9 Months in High-Dose Arm Presented at the 60th American Society of Hematology Annual Meeting MENLO PARK, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that results from IMbark, a Phase 2
Read more →GERNGeron Reports Updated Results from Phase 2 Portion of IMerge at the 60th American Society of Hematology Annual Meeting
MENLO PARK, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that updated results from Part 1 of IMerge, the Phase 2 portion of a Phase 2/3 clinical trial of imetelstat in lower risk myelodysplastic syndromes (MDS), were presented at the
Read more →GERNGeron to Host Analyst and Investor Event on December 10, 2018
MENLO PARK, Calif., Nov. 28, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the Company’s analyst and investor event will take place in New York, N.Y., on Monday, December 10, 2018. Management will be joined by clinical investigators from both IMer
Read more →GERNGeron to Present at Upcoming Investor Conferences in November
MENLO PARK, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present a company overview at the following investor conferences: Stifel 2018 Healthcare Con
Read more →GERNGeron Corporation Reports Third Quarter 2018 Financial Results and Recent Company Events
Imetelstat program transition proceeding, including plans to initiate Phase 3 portion of IMerge Abstracts for IMbark and IMerge accepted for oral presentation at American Society of Hematology Meeting (ASH) in December Conference call scheduled for 4:30 p.m. ET today MENLO PAR
Read more →GERNGeron Announces Two Oral Presentations on Imetelstat at Upcoming American Society of Hematology Annual Meeting
Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes and IMbark Primary Analysis in Myelofibrosis to be Presented MENLO PARK, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that clinical data related to imetelstat, the Com
Read more →GERNGeron to Announce Third Quarter 2018 Financial Results on November 1, 2018
MENLO PARK, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2018 financial results after the market closes on Thursday, November 1, 2018. The financial press release will be available on the Company
Read more →GERNGeron to Provide an Update on the Imetelstat Collaboration with Janssen on September 27, 2018
MENLO PARK, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will host a conference call to provide an update on the imetelstat collaboration with Janssen Biotech, Inc. (Janssen) on Thursday, September 27th at 8:00 a.m. ET. Part
Read more →GERNGeron Announces Discontinuation of Imetelstat Collaboration by Janssen
Geron regains global rights to imetelstat program Highlights reported for IMerge and IMbark Geron plans to initiate the Phase 3 portion of IMerge Conference call scheduled for 8:00 a.m. ET today MENLO PARK, Calif., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:
Read more →GERNGeron Corporation Reports Second Quarter 2018 Financial Results and Recent Company Events
MENLO PARK, Calif., July 31, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the three and six months ended June 30, 2018. Second Quarter and Year to Date 2018 Results For the second quarter of 2018, the Company reported a net loss
Read more →GERNGeron to Announce Second Quarter 2018 Financial Results on July 31, 2018
MENLO PARK, Calif., July 24, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that it will release its second quarter 2018 financial results after the market closes on Tuesday, July 31, 2018. The financial press release will be available on the Company’s w
Read more →GERNGeron Reports Imetelstat Oral Presentation at European Hematology Association Congress
MENLO PARK, Calif., June 18, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced the oral presentation of updated data from the ongoing original Part 1 of IMerge, the Phase 2/3 trial of imetelstat in lower risk myelodysplastic syndromes (MDS). The data was pr
Read more →GERNGeron Announces Oral Presentation at European Hematology Association Congress
MENLO PARK, Calif., May 17, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that an abstract describing clinical data regarding the telomerase inhibitor imetelstat has been selected for an oral presentation at the 23rd Congress of the European Hematology
Read more →GERNGeron Corporation Reports First Quarter 2018 Financial Results
MENLO PARK, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the first quarter ended March 31, 2018. First Quarter 2018 Results For the first quarter of 2018, the company reported operating revenues of $318,000 and op
Read more →GERNGeron 2018 Annual Meeting of Stockholders to be Held on May 15
MENLO PARK, Calif., April 17, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) will hold its 2018 Annual Meeting of Stockholders, on Tuesday, May 15, 2018, at 4:00 p.m. PDT. Geron’s stockholders are invited to attend the Annual Meeting in person at the company’s offices
Read more →GERNGeron to Present at the Needham Healthcare Conference
MENLO PARK, Calif., March 21, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the 17th Annual Needham Healthcare Conference in New York at 4:00 p.m. Eastern Tim
Read more →GERNGeron Corporation Reports Fourth Quarter and Annual 2017 Financial Results and Recent Events
MENLO PARK, Calif., March 16, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the fourth quarter and year ended December 31, 2017 and recent events. Fourth Quarter and Year-End 2017 Results For the fourth quarter of 2017, the compan
Read more →GERNP RESS R ELEASE D ATED M ARCH 16, 2018 Geron Corporation Reports Fourth Quarter and Annual 2017 Financial Results and Recent Events Conference Call Scheduled for 8:30 a.m. ET on Monday, March 19
PRESS RELEASE DATED MARCH 16, 2018 Geron Corporation Reports Fourth Quarter and Annual 2017 Financial Results and Recent Events Conference Call Scheduled for 8:30 a.m. ET on Monday, March 19 MENLO PARK, Calif., March 16, 2018 -- Geron Corporation (Nasdaq: GERN) today reported
Read more →GERNGeron Announces Conference Call to Discuss Fourth Quarter and Annual 2017 Financial Results
MENLO PARK, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) will announce its financial results for the fourth quarter and year ended December 31, 2017, on Friday, March 16, 2018, after the market close. Geron’s management will also host a conference cal
Read more →GERNJANUARY 2018
JANUARY 2018 CORPORATE PRESENTATION HANDOUT
Read more →GERNGeron Reports Imetelstat Presentations at American Society of Hematology Annual Meeting
Imetelstat Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes (MDS) Presented Analyst and Investor Meeting and Webcast at 8:30 a.m. ET on December 19, 2017 MENLO PARK, Calif., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced four p
Read more →GERNDATED DECEMBER 12, 2017 Geron Reports Imetelstat Presentations at American Society of Hematology Annual Meeting Imetelstat Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes (MDS) Presented An
Geron Reports Imetelstat Presentations at American Society of Hematology Annual Meeting Imetelstat Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes (MDS) Presented Analyst and Investor Meeting and Webcast at 8:30 a.m. ET on December 19, 2017 MENLO PARK, Calif.,
Read more →GERNGeron to Host Analyst and Investor Meeting and Webcast on December 19, 2017
MENLO PARK, Calif., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that the company’s analyst and investor meeting to discuss imetelstat clinical data will take place in New York, N.Y., on Tuesday, December 19, 2017. The presentation will begin
Read more →GERNGeron Announces First Patient Dosed in Expanded Part 1 of IMerge Clinical Trial in Myelodysplastic Syndromes
MENLO PARK, Calif., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that the first patient has been dosed in the expanded Part 1 of IMerge, the ongoing Phase 2/3 clinical trial of imetelstat in transfusion dependent patients with Low or Intermedi
Read more →GERNGeron Announces November Investor Conference Presentation Webcasts
MENLO PARK, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the following investor conferences: Stifel 2017 Healthcare Conference in New York
Read more →GERNP RESS R ELEASE D ATED N OVEMBER 1, 2017 Geron Corporation Reports Third Quarter 2017 Financial Results
Geron Corporation Reports Third Quarter 2017 Financial Results November 1, 2017 -- Geron Corporation (Nasdaq: GERN) today reported financial results for the three and nine months ended September 30, 2017. For the third quarter of 2017, the company reported a net loss of $6.
Read more →GERNDATED NOVEMBER 1, 2017 Geron Announces Presentations at American Society of Hematology Annual Meeting Imetelstat Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes to be Presented
Presentations at American Society of Hematology Annual Meeting Imetelstat Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes to be Presented November 1, 2017 -- Geron Corporation (Nasdaq: GERN) today announced that four abstracts related to the telomerase inhib
Read more →GERNGeron Announces Presentations at American Society of Hematology Annual Meeting
MENLO PARK, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that four abstracts related to the telomerase inhibitor imetelstat have been accepted for presentation at the 59th American Society of Hematology (ASH) Annual Meeting and Exposit
Read more →GERNGeron Corporation Reports Third Quarter 2017 Financial Results
MENLO PARK, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the three and nine months ended September 30, 2017. For the third quarter of 2017, the company reported a net loss of $6.9 million, or $0.04 per share, comp
Read more →GERNGeron Announces Fast Track Designation Granted to Imetelstat for Lower Risk Myelodysplastic Syndromes
MENLO PARK, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to imetelstat for the potential treatment of adult patients with transfusion-dependen
Read more →GERNGeron Announces Conference Call to Discuss Third Quarter 2017 Financial Results
MENLO PARK, Calif., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) will announce its financial results for the third quarter ended September 30, 2017, on Wednesday, November 1, 2017, after the market close. Geron’s management will also host a conference call fo
Read more →GERNGeron to Present at the Cantor Fitzgerald Healthcare Conference
MENLO PARK, Calif., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the Cantor Fitzgerald Global Healthcare Conference in New York at 1:40 p.m. Easter
Read more →GERNP RESS R ELEASE D ATED A UGUST 9, 2017 Geron Corporation Reports Second Quarter 2017 Financial Results MENLO PARK, Calif., A UGUST 9, 2017 -- Geron Corporation (Nasdaq: GERN) today reported financial results for the thre
PRESS RELEASE DATED AUGUST Geron Corporation Reports Second Quarter 2017 Financial Results AUGUST 9, 2017 -- Geron Corporation (Nasdaq: GERN) today reported financial results for the three and six months ended June For the second quarter of 2017, the company reported a net
Read more →GERNGeron Corporation Reports Second Quarter 2017 Financial Results
MENLO PARK, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the three and six months ended June 30, 2017. For the second quarter of 2017, the company reported a net loss of $6.4 million, or $0.04 per share, compared
Read more →GERNGeron Announces Updates to Imetelstat Clinical Development
MENLO PARK, Calif., July 31, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced updates to the clinical development plans for IMerge and IMbark, the ongoing trials of the telomerase inhibitor imetelstat in lower risk myelodysplastic syndromes (MDS) and relap
Read more →GERNGeron Corporation Reports First Quarter 2017 Financial Results and Recent Events
MENLO PARK, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the first quarter ended March 31, 2017 and recent events. First Quarter 2017 Results For the first quarter of 2017, the company reported operating revenues
Read more →GERNGeron 2017 Annual Meeting of Stockholders to be Held on May 9
First Quarter 2017 Financial Results Expected Same Day MENLO PARK, Calif., April 25, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) will hold its 2017 Annual Meeting of Stockholders, on Tuesday, May 9, 2017, at 4:00 p.m. PDT. Geron’s stockholders are invited to attend
Read more →GERNGeron Announces Completion of Second Internal Data Reviews for Imetelstat Trials Being Conducted by Janssen
Both IMerge and IMbark Continue in Lower Risk Myelodysplastic Syndromes and Relapsed or Refractory Myelofibrosis Conference Call Scheduled for 8:00 a.m. EDT Today, April 10 MENLO PARK, Calif., April 10, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced th
Read more →GERNGeron Announces Conference Call on April 10 at 8:00 A.M. Eastern Time
MENLO PARK, Calif., April 09, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) will host a conference call on April 10, 2017, at 8:00 a.m. Eastern Time to provide an update on the ongoing imetelstat Phase 2/3 trial in myelodysplastic syndromes and the Phase 2 trial in mye
Read more →GERNGeron Reports Imetelstat Presentation at American Association for Cancer Research Annual Meeting
MENLO PARK, Calif., April 05, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced a poster presentation by Janssen Research & Development, LLC describing non-clinical data on the telomerase inhibitor imetelstat at the 2017 American Association for Cancer Rese
Read more →GERNStipulation and Agreement of Settlement Richard W. Gonnello (admitted pro hac vice ) Megan M. Sullivan (admitted pro hac vice ) Katherine M. Lenahan (admitted pro hac vice ) FARUQI & FARUQI, LLP 685 Third Avenue, 26th Fl
Stipulation and Agreement Richard W. Gonnello (admitted pro hac vice ) Megan M. Sullivan (admitted pro hac vice ) Katherine M. Lenahan (admitted pro hac vice ) FARUQI & FARUQI, LLP 685 Third Avenue, 26th Floor New York, NY 10017 Telephone: 212-983-9330 Facsimile: 212-983-9331 Em
Read more →GERNGeron Announces Presentation at American Association for Cancer Research Annual Meeting
MENLO PARK, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced an abstract submitted by Janssen Research & Development, LLC describing non-clinical data on imetelstat has been accepted for presentation as a poster at the 2017 American Assoc
Read more →GERNGeron Corporation Reports Fourth Quarter and Annual 2016 Financial Results
MENLO PARK, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the fourth quarter and year ended December 31, 2016 and recent events. Fourth Quarter and Year-End 2016 Results For each of the fourth quarter of 2016 and
Read more →GERNGeron Announces Conference Call to Discuss Fourth Quarter and Annual 2016 Financial Results
MENLO PARK, Calif., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) will announce its financial results for the fourth quarter and year ended December 31, 2016, on Wednesday, March 1, 2017, after the market close. Geron’s management will also host a conference c
Read more →GERNJANUARY 2017
JANUARY 2017 CORPORATE PRESENTATION HANDOUT
Read more →GERNGeron Corporation Reports Third Quarter 2016 Financial Results and Recent Events
MENLO PARK, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the three and nine months ended September 30, 2016 and recent events. For the third quarter of 2016, the company reported a net loss of $3.6 million, or $(0
Read more →GERNGeron Announces Conference Call to Discuss Third Quarter 2016 Financial Results
MENLO PARK, Calif., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) will announce its financial results for the third quarter ended September 30, 2016, on Thursday, November 3, 2016, after the market close. Geron’s management will also host a conference call for
Read more →GERNGeron Provides Update on Imetelstat Trials Being Conducted by Janssen
MENLO PARK, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today provided updates on the clinical trials being conducted by Janssen Research & Development, LLC, of the telomerase inhibitor imetelstat. Planned internal reviews of initial data from both
Read more →GERNGeron Announces Conference Call on September 12 at 8:00 A.M. Eastern Time
MENLO PARK, Calif., Sept. 11, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) will host a conference call on September 12, 2016, at 8:00 a.m. Eastern Time to provide an update on the imetelstat Phase 2 trial in myelofibrosis and Phase 2/3 trial in myelodysplastic syndrom
Read more →GERNSummary Notice of Proposed Settlement ROBBINS ARROYO LLP BRIAN J. ROBBINS (190264) CRAIG W. SMITH (164886) JENNY L. DIXON (192638) GINA STASSI (261263) 600 B Street, Suite 1900 San Diego, CA 92101 Telephone: (619) 525-39
CRAIG W. SMITH (164886) JENNY L. DIXON (192638) 600 B Street, Suite 1900 Facsimile: (619) 525-3991 Plaintiff Joseph Oriente SUPERIOR COURT OF THE STATE JOSEPH ORIENTE, Derivatively on Behalf ) Case No. CIV528121 of GERON CORPORATION, ) ) (Consolidated with Case No
Read more →GERNDated August 3, 2016
Press Release Dated August 3, 2016 Geron Corporation Reports Second Quarter 2016 Financial Results and Recent Events Conference Call Scheduled for 4:30 p.m. EDT Today, August 3 MENLO PARK, Calif., August 3, 2016 -- Geron Corporation (Nasdaq: GERN) today reported financial
Read more →GERNGeron Corporation Reports Second Quarter 2016 Financial Results and Recent Events
MENLO PARK, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the three and six months ended June 30, 2016 and recent events. For the second quarter of 2016, the company reported a net loss of $8.6 million, or $0.05 pe
Read more →GERNGeron Announces Conference Call to Discuss Second Quarter 2016 Financial Results
MENLO PARK, Calif., July 27, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) will announce its financial results for the second quarter ended June 30, 2016, on Wednesday, August 3, 2016, after the market close. Geron’s management will also host a conference call for anal
Read more →GERNGeron Announces Issuance of U.S. Patents Related to Imetelstat
MENLO PARK, Calif., July 13, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced the recent issuance of three U.S. patents related to the company’s telomerase inhibitor, imetelstat. The first patent, U.S. 9,375,485, has claims covering the use of telomerase
Read more →GERNGeron Corporation Reports First Quarter 2016 Financial Results and Recent Events
MENLO PARK, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the first quarter ended March 31, 2016 and recent events. First Quarter 2016 Results For the first quarter of 2016, the company reported operating revenues
Read more →GERNP RESS R ELEASE D ATED M AY 5, 2016 Geron Corporation Reports First Quarter 2016 Financial Results and Recent Events Conference Call Scheduled for 4:30 p.m. EDT Today, May 5
Geron Corporation Reports First Quarter 2016 Financial Results and Recent Events Conference Call Scheduled for 4:30 p.m. EDT Today, May 5 Calif., May 5, 2016 -- Geron Corporation (Nasdaq: GERN) today reported financial results for the first quarter ended March 31, 2016 and r
Read more →GERNGeron Announces Conference Call to Discuss First Quarter 2016 Financial Results
MENLO PARK, Calif., April 27, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) will announce its financial results for the first quarter ended March 31, 2016, on Thursday, May 5, 2016, after the market close. Geron’s management will also host a conference call for analyst
Read more →GERNGeron Announces Two Imetelstat Poster Presentations at the American Association for Cancer Research Annual Meeting
MENLO PARK, Calif., April 20, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced two poster presentations of data from non-clinical studies of the telomerase inhibitor, imetelstat, at the 2016 American Association for Cancer Research (AACR) Annual Meeting he
Read more →GERNGeron Announces Presentations at American Association of Cancer Research Annual Meeting
MENLO PARK, Calif., March 17, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that two abstracts describing non-clinical data on imetelstat have been accepted for presentation as posters at the 2016 American Association of Cancer Research (AACR) Annual Me
Read more →GERNGeron Corporation Reports Fourth Quarter and Annual 2015 Financial Results
MENLO PARK, Calif., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the fourth quarter and year ended December 31, 2015 and recent events. Fourth Quarter and Year-End 2015 Results For 2015, the company reported net income o
Read more →GERNGeron Announces Conference Call to Discuss Fourth Quarter and Annual 2015 Financial Results
MENLO PARK, Calif., Feb. 17, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) will announce its financial results for the fourth quarter and year ended December 31, 2015, on Thursday, February 25, 2016, after the market close. Geron’s management will also host a conferenc
Read more →GERNGeron to Present at the RBC Capital Markets Healthcare Conference
MENLO PARK, Calif., Feb. 10, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the RBC Capital Markets 2016 Global Healthcare Conference in New York at 8:30 a.m.
Read more →GERNGeron Announces Initiation of Janssen Phase 2/3 Clinical Trial of Imetelstat in Myelodysplastic Syndromes
MENLO PARK, Calif., Jan. 14, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced the dosing of the first patient in a Phase 2/3 clinical trial to evaluate imetelstat in patients with myelodysplastic syndromes (MDS). This clinical trial, also referred to as th
Read more →GERNJANUARY 2016
JANUARY 2016 CORPORATE PRESENTATION HANDOUT
Read more →GERNGeron Announces December Conference Presentation Webcasts
MENLO PARK, Calif., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the following investor conferences: Piper Jaffray 27th Annual Healthcare Conferenc
Read more →GERNGeron to Present At the Stifel Healthcare Conference
MENLO PARK, Calif., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the Stifel 2015 Healthcare Conference in New York at 1:30 p.m. Eastern Time on Wedn
Read more →GERNGeron Corporation Reports Third Quarter 2015 Financial Results
MENLO PARK, Calif., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the third quarter ended September 30, 2015. For the third quarter of 2015, the company reported net income of $27.2 million, or $0.17 per share, compared t
Read more →GERNGeron Announces Conference Call to Discuss Third Quarter 2015 Financial Results
MENLO PARK, Calif., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) will announce its financial results for the third quarter ended September 30, 2015, on Thursday, November 5, 2015, after the market close. Geron’s management will also host a conference call for
Read more →GERNGeron to Present at the BIO Investor Forum
MENLO PARK, Calif., Oct. 13, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the BIO Investor Forum in San Francisco at 8:30 a.m. Pacific Time on Wednesday, Oct
Read more →GERNGeron Announces Initiation of Janssen Phase 2 Clinical Trial of Imetelstat in Myelofibrosis
MENLO PARK, Calif., Sept. 16, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced the dosing of the first patient in a Phase 2 clinical trial to evaluate imetelstat in patients with myelofibrosis (MF). This clinical trial, also referred to as the IMbarkTM stu
Read more →GERNGeron Corporation Reports Second Quarter 2015 Financial Results
MENLO PARK, Calif., Aug. 05, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the second quarter ended June 30, 2015. Second Quarter 2015 Results For the second quarter of 2015, the company reported a net loss of $9.4 million, or $0.
Read more →GERNGeron Corporation Reports First Quarter 2015 Financial Results and Recent Events
MENLO PARK, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results and recent events for the first quarter ended March 31, 2015. First Quarter 2015 Results For the first quarter of 2015, the company reported operating revenue
Read more →GERNGeron to Present at the Bank of America Merrill Lynch Healthcare Conference
MENLO PARK, Calif., April 27, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the Bank of America Merrill Lynch 2015 Healthcare Conference in Las Vegas at 3:40
Read more →GERNGeron to Present at the 14th Annual Needham Healthcare Conference
MENLO PARK, Calif., April 7, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John Scarlett, M.D., President and Chief Executive Officer, will present an overview of the company at the 14th Annual Needham Healthcare Conference in New York. The present
Read more →GERNof Geron s Current Report on Form 8-K filed on
Press Release Dated March Geron Corporation Reports Fourth Quarter and Annual 2014 Financial Results and Recent Organizational Resizing Conference Call Scheduled for 4:30 p.m. EST Today, March 3 Calif., March 3, 2015 -- Geron Corporation (Nasdaq: GERN) today reported finan
Read more →GERNJANUARY 2015
JANUARY 2015 CORPORATE PRESENTATION HANDOUT
Read more →GERNGeron Announces Early HSR Clearance for Global Strategic Collaboration with Janssen Menlo Park, Calif.
Early HSR Clearance for Global Strategic Collaboration with December 16, 2014 Geron Corporation (Nasdaq: GERN) announced today that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Acts of 1976 (
Read more →GERNSTIFEL 2014
STIFEL 2014 HEALTHCARE CONFERENCE PRESENTATION
Read more →GERNRISK FACTORS Our business is subject to various risks and uncertainties that may have a material adverse effect on our business, financial condition or results of operations. You should carefully consider the risks and u
Our business is subject to various risks and uncertainties that may have a material adverse effect on our business, financial condition or results of operations. You should carefully consider the risks and uncertainties described below, together with all of the other informat
Read more →GERNGeron Announces Removal of Full Clinical Hold on Imetelstat IND 2014 Third Quarter and Year-to-Date Financial Results Also Reported Menlo Park, Calif.
Geron Announces Removal of Full Clinical Hold on Imetelstat IND 2014 Third Quarter and Year-to-Date Financial Results Also Reported November 3, 2014 Geron Corporation (Nasdaq: GERN) announced today that the U.S. Food and Drug Administration (FDA) has removed the full clinic
Read more →GERNGeron Corporation Reports Second Quarter 2014 Financial Results Conference Call Scheduled for 4:30 p.m. EDT Today, August 11 th
Geron Corporation Reports Second Quarter 2014 Financial Results Conference Call Scheduled for 4:30 p.m. EDT Today, August 11th Calif., August 11, 2014 -- Geron Corporation (Nasdaq: GERN) today reported financial results for the second quarter ended June 30, 2014. Second Qua
Read more →GERN, DATED JUNE 12, 2014 Geron Reports Removal of Partial Clinical Hold on Myelofibrosis IST Menlo Park, Calif.
PRESS RELEASE, DATED JUNE 12, 2014 Geron Reports Removal of Partial Clinical Hold on Myelofibrosis IST Menlo Park, Calif., June 12, 2014 Geron Corporation (Nasdaq: GERN) announced today that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold o
Read more →GERNJEFFERIES 2014
JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE PRESENTATION
Read more →GERNGERON 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Securities Class Action Lawsuit Against Geron Corporation - GERN
NEW ORLEANS, LA--(Marketwired - May 9, 2014) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until May 13, 2014 to file lead plaintiff application
Read more →GERNGeron Corporation Reports First Quarter 2014 Financial Results Conference Call Scheduled for 4:30 p.m. EDT Today, May 1 st
Geron Corporation Reports First Quarter 2014 Financial Results Conference Call Scheduled for 4:30 p.m. EDT Today, May 1st MENLO PARK, Calif., May 1, 2014 -- Geron Corporation (Nasdaq: GERN) today reported financial results for the first quarter ended March 31, 2014. For th
Read more →GERN, DATED MARCH 20, 2014 Geron Reports Myelofibrosis IST Placed on Partial Clinical Hold Patients Deriving Clinical Benefit May Continue Imetelstat Treatment Menlo Park, Calif.
PRESS RELEASE, DATED MARCH 20, 2014 Geron Reports Myelofibrosis IST Placed on Partial Clinical Hold Patients Deriving Clinical Benefit May Continue Imetelstat Treatment Menlo Park, Calif., March 20, 2014 Geron Corporation (Nasdaq: GERN) announced today that patients curren
Read more →GERNGERON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Geron Corporation - GERN
NEW ORLEANS, March 17, 2014 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 13, 2014 to file lead plaintiff applications in a securities class action laws
Read more →GERNGeron Announces IND Clinical Hold Affecting Clinical Trials of Imetelstat in Essential Thrombocythemia and Multiple Myeloma Conference Call Today, March 12, at 8:30 a.m. EDT Menlo Park, Calif.
Geron Announces IND Clinical Hold Affecting Clinical Trials of Imetelstat in Essential Conference Call Today, March 12, at Menlo Park, Calif., March 12, 2014 Geron Corporation (Nasdaq: GERN) announced today that the company has received verbal notice from the U.S. Food and
Read more →GERNForward-Looking Statements This Current Report on Form 8-K, or Form 8-K, contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, whic
Forward-Looking Statements This Current Report on Form 8-K, or Form 8-K, contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the safe harbor created by that section
Read more →GERNSLIDES PRESENTED AT ASH 2013
SLIDES PRESENTED AT ASH 2013 ANALYST AND INVESTOR EVENT
Read more →GERNGeron Corporation Reports Second Quarter 2013 Financial Results Provides Update on Investigator - Sponsored Trial in Myelofibrosis Conference Call Scheduled for 4:30 p.m. EDT Today, August 8 th
Geron Corporation Reports Second Quarter 2013 Financial Results Investigator-Sponsored Trial in Myelofibrosis Conference Call Scheduled for 4:30 p.m. EDT Today, August 8th MENLO PARK, CA, August 8, 2013 Geron Corporation (Nasdaq: GERN) today reported financial results for
Read more →GERNJ.P. Morgan Healthcare Conference 2013 Presentation
J.P. Morgan Healthcare Conference 2013 Presentation
Read more →GERNRISK FACTORS Our business is subject to various risks, including those described below. You should carefully consider these risk factors, together with all of the other information included in our Annual Report on Form 1
Our business is subject to various risks, including those described below. You should carefully consider these risk factors, together with all of the other information included in our Annual Report on Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form 1
Read more →GERNto Geron's current report on Form 8-K filed on
Press Release Dated October 30, 2012 2012 Third Quarter Financial MENLO PARK, Calif., October 30, 2012 -- Geron Corporation (Nasdaq: GERN) today reported financial results for the three and nine months ended September 30, 2012. For the third quarter of 2012, the company repo
Read more →GERN, DATED SEPTEMBER 10, 2012 Geron Provides Update on Imetelstat Clinical Development Program Company to Host Conference Call Today at 8:30 a.m.
PRESS RELEASE, DATED SEPTEMBER 10, 2012 Geron Provides Update on Imetelstat Clinical Development Program Company to Host Conference Call Today at 8:30 a.m. ET MENLO PARK, Calif., September 10, 2012 - Geron Corporation (Nasdaq: GERN) today announced that, on the basis of an unp
Read more →GERNGeron Corporation Reports 2012 Second Quarter Financial Results and Events
Geron Corporation Reports 2012 Second Quarter Financial Results and Events MENLO PARK, Calif., July 31, 2012 Geron Corporation (Nasdaq: GERN) today reported financial results for the three and six months ended June 30, 2012. For the second quarter of 2012, the company reported
Read more →GERNJPMorgan 2012 Presentation
JPMorgan 2012 Presentation
Read more →GERNA Tribute to Alex Barkas PALO ALTO, Calif.--(BUSINESS WIRE)
PALO ALTO, Calif.--(BUSINESS WIRE)--November 23, 2011--Geron Corporation; Amicus Therapeutics; Complete Genomics, Inc.; Archemix Corp.; Neomend, Inc.; and TOPICA Pharmaceuticals, Inc. made the following tribute to Alexander Barkas: Our companies are greatly saddened to acknow
Read more →GERNGeron Corporation Reports 2011 Third Quarter Financial Results and Events MENLO PARK, Calif.--(BUSINESS WIRE)
Corporation Reports 2011 Third Quarter Financial Results and Events MENLO PARK, Calif.--(BUSINESS WIRE)--November 3, 2011--Geron Corporation (Nasdaq: GERN) today reported financial results for the three and nine months ended September 30, 2011. For the third quarter of 2011,
Read more →GERNGeron Corporation Reports 2011 Second Quarter Financial Results and Events MENLO PARK, Calif.--(BUSINESS WIRE)
Corporation Reports 2011 Second Quarter Financial Results and Events MENLO PARK, Calif.--(BUSINESS WIRE)--July 28, 2011--Geron Corporation (Nasdaq:GERN) today reported financial results for the three and six months ended June 30, 2011. For the second quarter of 2011, the comp
Read more →GERNGeron Corporation Reports 2011 First Quarter Financial Results and Highlights MENLO PARK, Calif.--(BUSINESS WIRE)
Corporation Reports 2011 First Quarter Financial Results and Highlights MENLO PARK, Calif.--(BUSINESS WIRE)--April 27, 2011--Geron Corporation (Nasdaq: GERN) today reported financial results for the three months ended March 31, 2011. For the first quarter of 2011, the company
Read more →GERNGeron Corporation Reports Fourth Quarter and Annual 2010 Financial Results Summary of 2010 Highlights MENLO PARK, Calif.--(BUSINESS WIRE)
Corporation Reports Fourth Quarter and Annual 2010 Financial Results MENLO PARK, Calif.--(BUSINESS WIRE)--February 24, 2011--Geron Corporation (Nasdaq: GERN) today reported financial results for the fourth quarter and year ended December 31, 2010. Fourth Quarter 2010 Results
Read more →GERNGeron Appoints David Greenwood President, Interim CEO and Director New Leadership Structure to Reflect Geron's Transition to Mid-Stage Clinical Development Company Conference Call/Webcast Scheduled for 10:00 A.M. EST Tod
Appoints David Greenwood President, Interim CEO and Director Leadership Structure to Reflect Geron's Transition to Mid-Stage Clinical Call/Webcast Scheduled for 10:00 A.M. EST Today MENLO PARK, Calif.--(BUSINESS WIRE)--February 9, 2011--Geron Corporation (Nasdaq:GERN) today a
Read more →GERNGeron Corporation Announces Closing of Its Public Offering of Common Stock MENLO PARK, Calif.--(BUSINESS WIRE)
Corporation Announces Closing of Its Public Offering of Common Stock MENLO PARK, Calif.--(BUSINESS WIRE)--December 10, 2010--Geron Corporation (Nasdaq: GERN) announced today the closing of its previously announced public offering of 17,391,305 shares of its common stock, as w
Read more →GERNGeron Corporation Announces the Pricing of Its Public Offering of Common Stock MENLO PARK, Calif.--(BUSINESS WIRE)
Corporation Announces the Pricing of Its Public Offering of Common Stock MENLO PARK, Calif.--(BUSINESS WIRE)--December 7, 2010--Geron Corporation (Nasdaq:GERN) today announced the pricing of an underwritten public offering of 17,391,305 shares of its common stock at a price to
Read more →GERNGeron Corporation Announces Proposed Public Offering of Common Stock MENLO PARK, Calif.--(BUSINESS WIRE)
Corporation Announces Proposed Public Offering of Common Stock MENLO PARK, Calif.--(BUSINESS WIRE)--December 6, 2010--Geron Corporation (Nasdaq: GERN) today announced that it is offering to sell shares of its common stock in an underwritten public offering. Geron also expects
Read more →GERNGeron Expands Clinical Oncology Pipeline with License and Collaboration Agreements with Angiochem Exclusive Worldwide License for Proprietary Peptides to Efficiently Transport Anti-Cancer Tubulin Inhibitor Agents into CN
Expands Clinical Oncology Pipeline with License and Collaboration Agreements with Angiochem Worldwide License for Proprietary Peptides to Efficiently Transport Anti-Cancer Tubulin Inhibitor Agents into CNS to Develop GRN1005, a Phase 2 Ready CNS-Active Taxane, for Brain Meta
Read more →GERNGeron Corporation Reports 2010 Third Quarter Financial Results and Events MENLO PARK, Calif.--(BUSINESS WIRE)
Corporation Reports 2010 Third Quarter Financial Results and Events MENLO PARK, Calif.--(BUSINESS WIRE)--October 28, 2010--Geron Corporation (Nasdaq:GERN) today reported financial results for the three and nine months ended September 30, 2010. For the third quarter of 2010, t
Read more →GERNGeron Initiates Clinical Trial of Human Embryonic Stem Cell-Based Therapy in Patients with Spinal Cord Injury First Patient Treated at Shepherd Center in Atlanta MENLO PARK, Calif.--(BUSINESS WIRE)
Initiates Clinical Trial of Human Embryonic Stem Cell-Based Therapy in Patients with Spinal Cord Injury Patient Treated at Shepherd Center in Atlanta MENLO PARK, Calif.--(BUSINESS WIRE)--October 11, 2010--Geron Corporation (Nasdaq: GERN) today announced the enrollment of the
Read more →GERNGeron to Proceed with First Human Clinical Trial of Embryonic Stem Cell-Based Therapy Geron to Study GRNOPC1 in Patients with Acute Spinal Cord Injury MENLO PARK, Calif.--(BUSINESS WIRE)
Proceed with First Human Clinical Trial of Embryonic Stem Cell-Based to Study GRNOPC1 in Patients with Acute Spinal Cord Injury MENLO PARK, Calif.--(BUSINESS WIRE)--July 30, 2010--Geron Corporation (Nasdaq:GERN) announced today that the U.S. Food and Drug Administration (FDA)
Read more →GERNGeron Corporation Reports 2010 Second Quarter Financial Results and Events MENLO PARK, Calif.--(BUSINESS WIRE)
Second Quarter Financial Results and Events MENLO PARK, Calif.--(BUSINESS WIRE)--July 29, 2010--Geron Corporation (Nasdaq:GERN) today reported financial results for the three and six months ended June 30, 2010. For the second quarter of 2010, the company reported a net loss
Read more →GERNGeron Corporation Reports 2010 First Quarter Financial Results and Highlights MENLO PARK, Calif.--(BUSINESS WIRE)
Corporation Reports 2010 First Quarter Financial Results and Highlights MENLO PARK, Calif.--(BUSINESS WIRE)--April 28, 2010--Geron Corporation (Nasdaq: GERN) today reported financial results for the three months ended March 31, 2010. For the first quarter of 2010, the company
Read more →GERNGeron Corporation Reports Fourth Quarter and Annual 2009 Financial Results and Highlights MENLO PARK, Calif.--(BUSINESS WIRE)
Corporation Reports Fourth Quarter and Annual 2009 Financial Results and MENLO PARK, Calif.--(BUSINESS WIRE)--February 25, 2010--Geron Corporation (Nasdaq: GERN) today reported financial results for the fourth quarter and year ended December 31, 2009. Fourth Quarter 2009 and
Read more →GERNof Geron Corporation, dated
Press Release of Geron Corporation, dated GERON CORPORATION ANNOUNCES WARRANT EXCHANGE MENLO PARK, Calif., January 15, 2010 - Geron Corporation (Nasdaq: GERN) today announced that it has entered into an agreement to exchange outstanding warrants held by certain institutional
Read more →GERNGeron and FDA Reach Agreement on Clinical Hold Company and Regulatory Agency Define Path to Re-Initiate Human Trials for Spinal Cord Injury MENLO PARK, Calif.--(BUSINESS WIRE)
FDA Reach Agreement on Clinical Hold and Regulatory Agency Define Path to Re-Initiate Human Trials for Spinal MENLO PARK, Calif.--(BUSINESS WIRE)--October 30, 2009--Geron Corporation (Nasdaq: GERN) today announced the company's plan to advance clinical development of its huma
Read more →GERNGeron Corporation Reports 2009 Third Quarter Financial Results and Events MENLO PARK, Calif.--(BUSINESS WIRE)
Corporation Reports 2009 Third Quarter Financial Results and Events MENLO PARK, Calif.--(BUSINESS WIRE)--October 29, 2009--Geron Corporation (Nasdaq:GERN) today reported financial results for the three and nine months ended September 30, 2009. For the third quarter of 2009, t
Read more →GERNGERON ANNOUNCES DIRECT EQUITY ISSUANCE Proceeds to be invested in ViaGen, Inc.
GERON ANNOUNCES DIRECT EQUITY ISSUANCE Proceeds to be invested in ViaGen, Inc. MENLO PARK, Calif., September 10, 2009 Geron Corporation (Nasdaq: GERN) today announced that it has sold shares of Geron common stock and issued warrants to purchase common stock to institutional
Read more →GERNGeron's IND for Spinal Cord Injury Placed on Hold MENLO PARK, Calif.--(BUSINESS WIRE)
IND for Spinal Cord Injury Placed on Hold MENLO PARK, Calif.--(BUSINESS WIRE)--August 18, 2009--Geron Corporation (Nasdaq:GERN) today announced that its IND (Investigational New Drug application) for GRNOPC1, a cell therapy for neurologically complete, subacute spinal cord in
Read more →Competitive Position
How GERN ranks across every disease it competes inCompetitive Position is a premium feature
See how GERN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial